DrugPatentWatch Database Preview
JETREA Drug Profile
Email this page to a colleague
» See Plans and PricingSummary for Tradename: JETREA
| Patents: | 8 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for JETREA |
Recent Clinical Trials for JETREA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Katholieke Universiteit Leuven | Phase 1 |
| Universitaire Ziekenhuizen Leuven | Phase 1 |
| Alcon Research | Phase 4 |
Pharmacology for JETREA
| Ingredient-type | Peptide Hydrolases |
Company Disclosures: US Patents for JETREA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | Thromb-X nv (Leuven, BE) | 2020-12-21 | RX | company | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | ThromboGenics NV (Leuven, BE) | 2022-12-06 | RX | company | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | ThromboGenics NV (Heverlee, BE) | 2022-12-06 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for JETREA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | OcuJect, LLC (Newport Beach, CA) | 2032-04-02 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | Corning Incorporated (Corning, NY) | 2031-10-25 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | Start Trial | OcuJect, LLC (Newport Beach, CA) | 2032-04-02 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for JETREA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2296705 | Start Trial |
| Japan | 5426063 | Start Trial |
| Australia | 2014332236 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JETREA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 13C0052 | France | Start Trial | PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313 |
| 537 | Finland | Start Trial | |
| PA2013020,C1581254 | Lithuania | Start Trial | PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
